Diabetic Kidney Disease, Endothelial Damage, and Podocyte-Endothelial Crosstalk

Cindy Lora Gil, Erika Hooker, and Bruno Larrivée

Diabetes-related complications are a significant source of morbidity and mortality worldwide. Diabetic kidney disease is a frequent microvascular complication and a primary cause of kidney failure in patients with diabetes. The glomerular filtration barrier is composed of 3 layers: the endothelium, glomerular basement membrane, and podocytes. Podocytes and the endothelium communicate through molecular crosstalk to maintain filtration at the glomerular filtration barrier. Chronic hyperglycemia affects all 3 layers of the glomerular filtration barrier, as well as the molecular crosstalk that occurs between the 2 cellular layers. One of the earliest events following chronic hyperglycemia is endothelial cell dysfunction. Early endothelial damage is associated with progression of diabetic kidney disease. However, current therapies are based in controlling glycemia and arterial blood pressure without targeting endothelial dysfunction. Disruption of the endothelial cell layer also alters the molecular crosstalk that occurs between the endothelium and podocytes. This review discusses both the physiologic and pathologic communication that occurs at the glomerular filtration barrier. It examines how these signaling components contribute to podocyte foot effacement, podocyte detachment, and the progression of diabetic kidney disease.

© 2020 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

A CHALLENGING CLINICAL PROBLEM

Diabetic kidney disease (DKD) is a frequent microvascular complication of diabetes and is the cause of kidney failure in ~40% of people with diabetes. In 2015, it was estimated that more than 415 million people had diabetes worldwide, and it is expected that by 2040, the prevalence may increase to 642 million, with disproportionate growth in low- and middle-income countries. The recent surge of epidemiologic studies linking microvascular complications to diabetes highlights the urgent need to develop therapeutic alternatives that target microvascular complications to diminish these alarming figures. Few therapies are targeting endothelial damage or pathologic podocyte-endothelial crosstalk, both of which play a critical role in DKD progression.

CELLULAR COMPONENTS OF THE GLOMERULAR FILTRATION BARRIER

Glomeruli are composed of 3 distinct layers necessary for the filtration of plasmatic molecules and electrolytes: the endothelium, glomerular basement membrane (GBM), and podocytes (Fig 1A). The endothelium constitutes the first layer of the glomerular filtration barrier and is characterized by the presence of fenestrations, measuring between 70 and 100 nm in diameter. It is coated on the luminal surface by a gelatinous glycoprotein-rich structure called the glycocalyx that separates and protects endothelial cells from the flowing blood. Endothelial cells are separated from podocytes by the GBM, a complex mesh of extracellular matrix proteins, including type IV collagen, laminins, fibronectins, and proteoglycans. The components of the GBM are secreted from both podocytes and endothelial cells to form a hybrid basement membrane. The podocytes are an epithelial cell layer that can be divided into 3 segments: cell body, microtubule-rich major processes, and actin-based foot processes. The molecular interactions that occur at the slit diaphragm, an adhesive structure that joins individual foot processes, allow podocytes to control filtration inside glomeruli. Single-cell RNA sequencing experiments in mice revealed that endothelial cells make up between 2% and 3% of total kidney cells in wild-type mice, whereas podocytes make-up ~0.2% of the total cellular portion of the kidney.

In contrast, kidney single-cell transcriptomic analysis of human normal kidney biopsy specimens reveals a higher percentage (~11.5%) of endothelial cells in the kidney. Inside the glomerulus, endothelial cells make up ~12% of cells inside the glomerulus, while podocytes and mesangial cells are 80% and 2%, respectively.

Both the endothelial and podocyte cellular layers interact directly with the GBM and each other through various secreted factors (Fig 1B). Recent studies also show that several cellular populations in the kidney can communicate through secreted exosomes. In particular, in vitro models have demonstrated that exosomes can be purified from glomerular endothelial cells and induce biological effects in podocytes. Exosomes can contain messenger RNA and microRNA and protein, allowing signaling to occur. Intriguingly, the quantity and contents of exosomes has been demonstrated to be altered in various kidney diseases, including DKD.

PODOCYTE-ENDOTHELIAL CELL CROSSTALK AND REGULATION OF THE GLOMERULAR FILTRATION BARRIER

Molecules secreted from both podocytes and endothelial cells help stabilize the slit diaphragm and maintain the structural integrity of both the endothelial and podocyte
layers. One of the most well-established pathways involved in podocyte-endothelial cell crosstalk is the vascular endothelial growth factor (VEGF) signaling pathway. The VEGF family consists of 5 ligands (VEGF-A-D and placental growth factor) and 3 receptors (VEGFR1-3). In the kidney, podocytes are a primary source of VEGF-A. Podocyte-derived VEGF-A is necessary for the survival and function of glomerular endothelial cells. In the kidney, both loss and gain of podocyte-derived VEGF-A leads to endothelial dysfunction, podocyte foot effacement, and thickening of the GBM, demonstrating the importance of VEGF signaling to the glomerulus. Reduced VEGF levels can result in endothelial cell death leading to podocyte loss and thickening of the GBM, whereas excessive VEGF production results in neovascularization leading to pathologic microangiopathy.

The primary receptor for VEGF-A, VEGFR2 (FLK-1/KDR), is expressed by both endothelial and podocyte cells, indicating that both cell types may be responsive to local changes in VEGF-A concentration. Genetic and pharmacologic removal of the VEGF-A ligand clearly disrupts both podocyte and endothelial cell function. However, podocyte-specific inhibition of VEGF-A signaling through deletion of the VEGFR2 in podocytes does not impair podocyte function or alter podocyte morphology. These studies suggest that the disruption of podocyte function after VEGF-A depletion arises from endothelial cell dysfunction and a disruption of podocyte-endothelial crosstalk, rather than impaired VEGF-A signaling in podocytes.

In contrast to VEGF signaling, which is necessary for maintenance of the glomerular filtration barrier, transforming growth factor β (TGFβ) signaling is largely detrimental to both podocytes and endothelial cells in the glomerulus. TGFβ1 belongs to the TGF superfamily that comprises several members, including TGFβ1-3, activins, bone morphogenetic proteins (BMPs), and growth differentiation factor ligands and their receptors. Upon ligand binding to a complex of TGFβ receptors (TGFβRs), the Smad proteins can be phosphorylated and translocate to the nucleus to modify gene transcription. While during kidney development, many BMP and TGFβ ligands are expressed, in adult human glomeruli, ligands of the TGFβ family have little to no expression. Multiple studies indicate that activating TGFβ signals can lead to podocyte apoptosis and foot effacement, decreasing VEGF production and ultimately leading to endothelial cell death. In many cell types, TGFβ signaling has been implicated in epithelial- (or endothelial)-to-mesenchymal transitions. Both in vitro and in vivo studies indicate that TGFβ1 treatment can dedifferentiate or induce epithelial-to-mesenchymal transitions in podocytes.

Endothelial cells may also be affected by the production of TGFβ1. One in vivo study demonstrated that removal of the TGFβR, TGFβRII, in endothelial cells was sufficient to inhibit endothelial-to-mesenchymal transition from occurring in 2 kidney disease models.

Other soluble molecules have also been shown to mediate the crosstalk between endothelial cells and podocytes. Angiopoietin 1, which is produced by podocytes, can promote microvascular growth through the Tie2 receptor expressed in glomerular endothelial cells. Interestingly, angiopoietin 2, a natural antagonist of Tie2, has been found to be upregulated in DKD, and its podocyte-specific overexpression can lead to endothelial apoptosis and albuminuria. Stromal cell–derived factor 1, which is produced by podocytes, can elicit signaling in neighboring endothelial cells through the CXCR4 receptor. Endothelial-specific inactivation of CXCR4 has been shown to adversely affect renal angiogenesis, and inactivation of stromal cell–derived factor 1 diabetic mice has been shown to prevent albuminuria. Finally, Sema3a, a member of the semaphorin family, is produced by podocytes and can bind to the receptor neuropilin 1 expressed in glomerular endothelial cells, where it can modulate VEGF/VEGFR2 signaling. Podocyte-specific overexpression of Sema3a has been shown to result in endothelial apoptosis, whereas its deletion is accompanied by endothelial overgrowth. These examples demonstrate how secreted signals exchanged between podocytes and endothelial cells regulate both the survival and maintenance of these 2 cellular populations and the GBM.

**Figure 1 (previous page).** Endothelial-podocyte crosstalk. (A) Transmission electron micrograph of a normal mouse glomerular filtration barrier shows podocyte (P) foot process, glomerular basement membrane (GBM), and endothelial cells (EC; scale bar: 500 nm). (B) Under physiologic conditions (left), various secreted factors are exchanged between podocytes and endothelial cells to allow for maintenance of the glomerular filtration barrier. During diabetic nephropathy (right), increased reactive oxygen species (ROS) production can lead to thinning of the glyocalyx of the endothelium, as well as cellular damage to both endothelial cells and podocytes. Overactivation of several pathways leads to endothelial dysfunction, podocyte foot effacement, and eventually podocyte detachment. Abbreviations: eNOS, endothelial nitric oxide synthase; ETAR, endothelin A receptor; TGFβ, transforming growth factor β; TRPC6, transient receptor potential canonical 6.
these pathways is endothelial dysfunction. Importantly, early endothelial damage is associated with the progression of DKD.\textsuperscript{18,19}

Under physiologic conditions, glucose is taken up by endothelial cells through various glucose transporters. Endothelial cells express primarily glucose transporter 1 (GLUT1), and the expression of GLUT1 in endothelial cells has not been reported to change during hyperglycemic conditions.\textsuperscript{40} Despite a low dependency on the mitochondria, endothelial cells, which rely primarily on anaerobic glycolysis for energy production,\textsuperscript{41} demonstrate mitochondrial defects under diabetic conditions that contribute to microvascular dysfunction. Both mitochondrial fission and a switch to glycolysis have been reported to lead to a loss of barrier function and a loss of podocytes during hyperglycemic conditions.\textsuperscript{42,43} Endothelial cells also experience higher ROS levels due to mitochondrial dysfunction from hyperglycemia.\textsuperscript{42,43} Interestingly, in a model of glomerulosclerosis, scavenging of mitochondrial ROS produced by endothelial cells could prevent podocytes loss,\textsuperscript{44} suggesting that ROS production in one cell type may affect the function of the others.

In addition to the damage caused by metabolic dysregulation and ROS accumulation, chronic hyperglycemia can induce vascular dysfunction by decreasing glycocalyx thickness.\textsuperscript{45} This event has been associated with microalbuminuria in patients with DKD.\textsuperscript{46} Increased plasma levels of both hyaluronan, a key glycosaminoglycan abundantly present in the glycocalyx, and the enzyme that degrades hyaluronan, hyaluronidase, have been observed in patients with diabetes.\textsuperscript{47} Plasma levels of other glycosaminoglycan components, such as hemagglutinin glycoprotein, heparan sulfate, and syndecan, have also been observed to increase during chronic hyperglycemia.\textsuperscript{48} The increased levels of these factors in plasma is thought to be a consequence of glycocalyx degradation.\textsuperscript{49} Hyperglycemic conditions also produce ROS that can alter glycosaminoglycans, in particular hyaluronan, ultimately disrupting its polymerization.\textsuperscript{50,51}

Finally, endothelial damage is also strongly involved in promoting the expression of inflammatory molecules such as cytokines and CP-1 that affect podocytes.\textsuperscript{52} The proinflammatory environment in the diabetic kidney also leads to an increase of the adhesion molecules intercellular adhesion molecule 1, vascular cell adhesion molecule 1, P-selectin, and E-selectin on the surface of endothelial cells.\textsuperscript{53-55} A recent study demonstrated that expression of the adhesion marker vascular cell adhesion molecule 1 can be directly regulated by secreted cytokines and chemokines such as CCL2 coming from podocytes.\textsuperscript{56}

Functionally, the mentioned studies are supported by data demonstrating that increased expression of various adhesion molecules is associated with increased infiltration of distinct immune cell populations in a rat model of diabetes.\textsuperscript{57} The increased expression of leukocyte adhesion molecules on endothelial cells also correlated with increased proteinuria in this model.\textsuperscript{57} Furthermore, single-cell or single-nucleus transcriptomic studies in both humans and mice demonstrated increased immune cell infiltration in diabetic kidneys.\textsuperscript{58,59} In mice, M1 macrophages were found to be the predominant immune cell type inside the glomerulus, whereas in human kidney biopsy samples, T cells represented 49% of the infiltrating leukocytes in the diabetic kidney.\textsuperscript{58,59} It is important to note that the mouse model used was an endothelial nitric oxide (NO) synthase (eNOS) knock-out streptozocin-induced model of diabetes.\textsuperscript{58} Because eNOS is globally reduced, this loss may itself affect the immune system when compared with wild-type mice.

### PODOCYTE ALTERATIONS IN DIABETES

Endothelial dysfunction is typically accompanied by podocyte foot effacement or detachment and a progressive decrease in estimated glomerular filtration rate when poor glycemic control and inadequate blood pressure are
Podocyte Foot Effacement

Podocyte foot effacement in DKD is a major cause of proteinuria. Disruption of the slit diaphragm (SD) is a feature of most instances of podocyte foot effacement. Disruption of glomerular SD proteins, such as nephrin in DKD, has been experimentally demonstrated to play a role in albuminuria.\(^{61-62}\) One study histologically compared nephrin expression in 15 patients with type 2 diabetic versus 12 nondiabetic control patients. The authors identified a statistically significant decrease in nephrin and podocin expression in 100% of patients with DKD diagnosed and exhibiting either micro- or macroalbuminuria, leading them to conclude that nephrin could be used as an indicator of early kidney damage in DKD.\(^{78, 80}\) Patients with DKD also exhibit decreased messenger RNA and protein expression of nephrin, which has been strongly correlated to albuminuria in patients with DKD.\(^{61, 62}\)

Chronic hyperglycemia can also lead to disruption of nephrin and the SD through increased expression of the transient receptor potential canonical 6 (TRPC6) calcium channel.\(^{63}\) TRPC6 binds to phospholipase C\(\gamma\)1 (PLC\(\gamma\)1) and mediates the influx of calcium.\(^{64}\) Nephrin-mediated activation of PLC\(\gamma\)1, a known regulator of calcium signalling, also leads to increased entry of calcium into podocytes.\(^{85}\) This increased calcium influx causes reorganization of actin filaments that ends in SD disruption.\(^{66-68}\) Intriguingly, a recent study also demonstrates that zonula occludens-1 (ZO-1) on the foot process of podocytes is reorganized after calcium influx under hyperglycemic conditions in a TRPC6-dependent manner, suggesting that TRPC6 may directly contribute to foot-process effacement.\(^{69}\)

Nephrin also plays an important role regulating podocyte insulin sensitivity.\(^{79}\) Knockdown of nephrin in podocytes blocks the ability of these cells to respond to insulin and impairs the ability of podocytes to uptake glucose.\(^{79}\) The cytoplasmic domain of nephrin enables the docking of glucose transporters GLUT1 and GLUT4 in the plasma membrane of podocytes.\(^{79}\) Surprisingly, insulin sensitivity effects of nephrin expression are conserved even in an insect model of chronic hyperglycemia. Expression of the nephrin-like protein Sn5 in Drosophila was reduced under conditions of chronic hyperglycemia. Loss of Sn5 expression also led to actin rearrangement, loss of the nephrocyte diaphragm function, and dysregulation of the insulin signaling pathway. Using this fly model of chronic hyperglycemia, the authors identified a novel transcription factor negatively regulating nephrin expression.\(^{70}\) Reduction of Drosophila Knot or mouse Ebf2 conferred resistance to glucose and stabilization of Sn5 and nephrin at the slit diaphragm in nephrocytes and podocytes, respectively.\(^{70}\) This and other studies suggest that loss of nephrin during conditions of chronic hyperglycemia contributes to podocyte insulin resistance. However, some studies have also reported elevations in nephrin expression and location in patients with types 1 and 2 diabetes,\(^{56, 61}\) which may be related to the duration of diabetes and hypertension.

Podocyte Detachment

In addition to podocyte foot effacement, podocyte detachment has been observed in histology samples of patients with diabetes.\(^{71, 72}\) Podocyte detachment or loss can be measured by examining the number of Wilms tumor 1 (WT-1)–expressing cells. A reduction in WT-1–positive podocyte cell number and density per glomerulus has been linked to the development of both proteinuria and kidney disease progression.\(^{71, 72}\)

Various mechanisms have been described regarding the way in which podocytes can detach from the GBM. One of the earliest phenomena taking place in podocyte detachment is podocyte hypertrophy.\(^{80}\) Under conditions of chronic hyperglycemia, while endothelial and mesangial cells proliferate, podocytes are unable to proliferate and may increase in size to cover the glomerular tuft.\(^{75, 76}\) In some instances, chronic hyperglycemia can also induce hypertrophy of both the podocyte and mesangial cells.\(^{75}\) Hypertrophic mesangial cells are not able to properly synthesize the extracellular matrix, causing worsened hypertrophy of podocytes.\(^{81}\) When the stress is removed, podocytes fail to return to their normal size.\(^{82}\) This adaptive response of podocytes leads to both molecular and structural changes to the podocyte and eventually results in deterioration of their function and adhesion to the GBM. Podocytes may increase the number of occludin-based tight junctions to counteract the loss of their function during hypertrophy. Increasing the occludin-type tight junctions temporarily prevents podocyte foot effacement but is not sustainable over the long term. Eventually, the loss of the SD and junctions leads to detachment of the podocyte from the GBM.\(^{83, 84}\) Moreover, mechanical forces such as increased glomerular pressure that are associated with hyperfiltration may also exacerbate podocyte hypertrophy and disrupt the connection between podocytes and GBM.\(^{73, 82}\) Importantly, hyperfiltration is frequently observed in diabetic patients.\(^{85, 86}\)

At the molecular level, the physical disruption of podocyte-GBM attachment is often observed as a disruption of integrin signaling. Numerous studies in cultured podocytes have shown that exposure to high glucose levels reduces \(\alpha 3\beta 1\) integrin expression.\(^{87, 88}\) This reduction in \(\alpha 3\beta 1\) integrin has also been reported in both human patients with DKD and streptozotocin-induced diabetic rats.\(^{87}\) Loss or reduction of \(\alpha 3\beta 1\) integrin can lead to focal detachment of podocytes from the GBM and ultimately separation of the podocyte from the GBM.\(^{76}\) Another common cause for a decrease in podocyte number is cellular apoptosis. Podocytes exposed to high glucose levels increase ROS production and activate p38 mitogen-activated protein kinase (p38MAPK) signaling, a mediator of mitochondrial stress. Both these signaling events can
Table 2. Molecules Involved in Pathologic Crosstalk Between Podocytes and Endothelial Cells During Diabetic Nephropathy

| Molecules | Pathologic Processes | Potential Clinical Therapy | References |
|-----------|----------------------|----------------------------|------------|
| VEGF-A, VEGF-B, VEGF-C | VEGF-A: angiogenesis of microvessels, decrease in glycocalyx, modified GBM VEGF-B: fatty acid transport (lipid accumulation) VEGF-C: reduces VEGF-A-induced albumin permeability | Anti-VEGF antibodies, small molecule inhibitors (SU5416), angiotatin, endostatin | 89, 90, 93-96 |
| TGFβ1, TGFβ3, BMP7, LTPB1 | TGFβ1: endothelial cell apoptosis, renal microangiopathy, epithelial-mesenchymal transition of podocytes, endothelial-mesenchymal transition of podocytes BMP7: exogenous BMP7 improves GFR LTPB1: regulates targeting of TGFβ complexes | Neutralizing antibodies, antisense oligonucleotides, small molecule inhibitors (SISI3) | 14, 58, 59, 62, 72, 91, 99-101 |
| ET-1 | Mitochondrial oxidative stress, endothelial cell dysfunction, loss of slit diaphragm organization | Endothelin receptor antagonists (Sitaxentan, Atrasentan) | 44, 92, 97, 98 |

Note: All molecules are upregulated.
Abbreviations: BMP7, bone morphogenetic protein 7; ET-1, endothelin 1; GBM, glomerular basement membrane; GFR, glomerular filtration rate; LTPB1, latent transforming growth factor β-binding protein 1; TGFβ, transforming growth factor β; VEGF, vascular endothelial growth factor.

Pathologic Podocyte-Endothelial Cell Crosstalk in DKD

Multiple secreted factors that facilitate the physiologic crosstalk between podocytes and endothelial cells are affected in hyperglycemic conditions (Fig 1B and Table 2).14,44,48,59,62,72,89-101.

Clinical data have demonstrated a significant increase in circulating VEGF levels in diabetic patients.102 It has been demonstrated by multiple groups that persistent high glucose levels stimulate podocytes to produce VEGF-A.103,104 Multiple factors can lead to altered VEGF-A secretion and availability from the podocytes. WT-1, a podocyte-specific transcription factor, can regulate the gene expression of various genes involved in the pathogenesis of DKD including VEGF-A.105 Furthermore, VEGF in the diabetic kidney can also be increased by the accumulation of AGEs during chronic hyperglycemia.106,107 AGE accumulation in all tissues has been shown to lead to VEGF overproduction in vivo and in vitro.75 Additionally, modifications of the extracellular matrix components, such as the reduction of heparan sulfate proteoglycans (HSPGs) in DKD, also affect the availability and affinity of growth factor ligands such as VEGF-A. HSPGs situated on the cell surface or in the extracellular matrix can mediate receptor-ligand interactions of VEGF-A, basic fibroblast growth factor, and heparin-binding epidermal growth factor.108 Increased expression and activity of heparanases in DKD decreases HSPG levels, ultimately reducing growth factor signaling in the cell populations that express these receptors.109

The excessive levels of VEGF-A produced by podocytes induce the endothelium to undergo angiogenesis, leading to the formation of immature microvessels in the glomerulus.89,109,110 Increased circulating VEGF also leads to alterations of the GBM and a decrease in the glycocalyx, which further promotes leaky permeable vessels in DKD.90 At the molecular level, the overproduction of VEGF in DKD also leads to oxidative stress in both endothelial cells and podocytes.111 VEGF signaling in endothelial cells increases eNOS activity.91 Although in physiologic conditions, activation of VEGFR2 will activate PI3K and Akt, which phosphorylate and activate eNOS and increase NO production,91 in chronic hyperglycemia, VEGFR2 over-activation increases ROS production, in particular superoxide (O2•−), worsening endothelial damage.72,112 ROS molecules can also decrease the bioavailability of NO by forming the damaging reactive nitrogen species, nitrate (NO3•−).72 ROS and reactive nitrogen species production have also been associated with podocyte damage and foot effacement.113 In agreement with these data, increased eNOS activity can promote podocyte detachment and is also associated with increased microalbuminuria levels in diabetic patients.62

VEGF-A is not the only ligand of the VEGF family that is increased in models of diabetes. A recent study demonstrated that VEGF-B is also increased in 3 separate rodent models of diabetes. VEGF-B upregulation in diabetic mice increased fatty acid transport across the endothelium, ultimately resulting in lipid accumulation within the podocyte. Removal of VEGF-B could restore the function of the glomerular filtration barrier.114 Furthermore,
increasing expression of VEGF-C, secreted by podocytes, could also reduce VEGF-A-induced albumin permeability. This effect was dependent on the presence of the glycoscalyx on endothelial cells and was mediated by VEGFR2 and VEGFR3. 14

In addition to the striking effects on the VEGF ligands, hyperglycemic conditions also increase expression of the TGFβ family of ligands. 14,58 TGFβ1, TGFβ3, and BMP7 are all reported to be increased in models of DKD. 14,58 Expression of LTBP1 (latent-transforming growth factor beta-binding protein 1), a regulator of TGFβ signaling, has also been reported to be altered in human DKD. 15 Exosomes isolated from glomerular endothelial cells treated with high glucose were found to induce an increase in TGFβ1, both locally and in podocytes exposed to the purified exosomes. 14 Autocrine TGFβ signaling by endothelial cells promotes endothelial cell apoptosis and ultimately worsens kidney microangiopathy in DKD. 72,116 Increased TGFβ production can also be detrimental to podocytes. When treated with endothelial exosomes, podocytes also went through an epithelial to mesenchymal transition that was associated with a loss of barrier function. 14 Other studies have also indicated that activation of the TGFβ receptor, TGFβR1, in podocytes was associated with increased release of endothelin 1 (ET-1) from podocytes, podocyte apoptosis, and endothelial dysfunction. 44 Endothelin A receptor (ETAR) activation in the endothelium by podocyte-derived ET-1 caused mitochondrial oxidative stress and endothelial cell dysfunction, ultimately leading to podocyte drop out and apoptosis. These effects could be prevented by both ROS scavenging and inhibition of ETAR. 44 In agreement with these data, increased ET-1 levels have also been found in plasma of patients with diabetes type 2. 117 Podocytes detect the increased ET-1 levels through the ETAR receptor. Activation of ETAR allows rapid entry of calcium into the podocytes, which leads to rearrangement and loss of the organization of the actin filaments in the SD. 92 Activation of the ETAR in podocytes also regulates the glomerular filtration barrier through indirect modifications of the components of the SD in response to endothelial-derived ET-1. 118 These perturbations to the actin cytoskeleton and the SD have a direct impact on the glomerular filtration barrier. 118 Intriguingly, a recent study indicates that ETAR expression can be induced on cultured murine glomerular endothelial cells in response to podocyte-derived ET-1 induced by TGFβR1 activation. 119 Activation of ETAR, by decreasing the thickness of the endothelial glycoscalyx and promoting mitochondrial ROS production in endothelial cells, leads to endothelial damage, which can in turn result in albuminuria in patients with diabetes. 119

As DKD progresses, podocytes respond to signals from the endothelium as described and eventually detach and drop out. 120 When this occurs, endothelial cells are deprived of essential growth factors such as VEGF-A. Without these essential growth factors, endothelial cells will also fail to survive exacerbating the vicious cycle of pathologic endothelial-podocyte crosstalk.

**PRECLINICAL OR CLINICAL USE OF MOLECULES TARGETING ENDOTHELIAL DYSFUNCTION OR PODOCYTE-ENDOTHELIAL CROSSTALK IN DKD**

The identification of clinically relevant biomarkers of the crosstalk between endothelial cells and podocytes is hampered by issues that need to be addressed. To date, there is no single test that can identify endothelial cell dysfunction in patients. Endothelial dysfunction is typically characterized by a reduction in endothelium-dependent vasodilation, primarily due to a decline in endothelium-derived NO. Forearm reactive hyperemia, a measure of microvascular vasodilation that is mediated in part by NO, is impaired in patients with chronic kidney disease and kidney failure and is associated with albuminuria, although it cannot be necessarily associated with podocyte dysfunction. However, dysfunctional endothelial cells will release factor(s) that mediate damage and depletion of adjacent podocytes in response to stress. As such, a combination of functional measurements of vascular function combined with systemic or local evaluation of such stress-induced factors, including TGFβ or ET-1, in patients with diabetes at risk for developing chronic kidney disease could provide strategies to assess crosstalk events that underlie observed increases in glomerular permeability to albumin in kidney disease.

Although intensive control of glucose and blood pressure remain the clinical gold standards to deter the progression of DKD, new treatments that aim to prevent endothelial damage or restore endothelial function could be an effective strategy for preventing or even reversing DKD. Several drugs have been evaluated for their potential to alleviate vascular dysfunction in the glomerular endothelium. Administration of neutralizing monoclonal anti-VEGF antibodies to type 1 and type 2 diabetic animals decreases albuminuria and glomerular hypertrophy, indicating the efficacy of anti-VEGF therapy against DKD. 93,121 Furthermore, SU5416, a pan-VEGFR tyrosine kinase inhibitor, has also been reported to reduce albuminuria in type 2 diabetic mice. 94 Other molecules targeting VEGF signaling in the glomerular endothelium are also being evaluated in preclinical studies, including angiotatin, a proteolytic fragment of plasminogen, 95 and endostatin, which interacts with α5β1 integrin, leading to the inhibition of focal adhesion kinase and subsequent inhibition of VEGF-induced MAPKs. 96

Preclinical and clinical studies have shown that several endothelin receptor antagonists, including sitaxsentan 97 and atrasentan, 98 can prevent proteinuria and have nephroprotective potential in experimental models of DKD. Several strategies targeting TGFβ signaling, including neutralizing antibodies, antisense oligonucleotides, or inhibitors such as SISI3 can also prevent endothelial-mesenchymal transition and renal fibrosis in experimental models of nephropathy. 99,101 Gliquidone can ameliorate the diabetic symptoms of DKD through inhibiting Notch signaling in the endothelium, improving antioxidative
CONCLUSIONS
Numerous cross-sectional studies have shown that albuminuria in DKD is linked to endothelial and podocyte dysfunction and loss. There is still much to explore considering the numerous signaling pathways involved in endothelial-podocyte interactions, which makes this challenging clinical problem much more complex. To date, the crosstalk between endothelial cells and podocytes can only be assessed indirectly through the expression of mediators. Improved methods to identify signaling pathways and regulators have greatly improved our understanding of glomerular cross-communication in vivo and should lead to the identification of new targets for the prevention and treatment of glomerular diseases to help reduce the growing number of patients with diabetes who may require dialysis.

ARTICLE INFORMATION
Authors’ Full Names and Academic Degrees: Cindy Lora Gil, MSc, MD, Erika Hooker, PhD, and Bruno Larivée, PhD.
Authors’ Affiliations: Department of Biomedical Sciences (CLG), Maisonneuve-Rosemont Hospital Research Centre (CLG, EH, BL), and Department of Ophthalmology (BL), University of Montreal, Montréal, QC, Canada.
Address for Correspondence: Bruno Larivée, PhD, Maisonneuve-Rosemont Hospital, 5415 boul. L’Assomption, Montréal, QC, Canada, H1T 2M. E-mail: bruno.larivée@umontreal.ca
Support: This work was supported by a grant-in-aid from the Heart and Stroke Foundation of Canada and from the Canadian Institutes of Health Research (363450). Dr Larivée was a recipient of a New Investigator Award from the Heart and Stroke Foundation of Canada.
Financial Disclosure: The authors declare that they have no relevant financial interests.
Acknowledgements: CLG and EH had an equal contribution.
Peer Review: Received May 26, 2020. Evaluated by 1 external peer reviewer, with direct editorial input from an Associate Editor and the Editor-in-Chief. Accepted in revised form October 18, 2020.

REFERENCES
1. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032-2045.
2. Gheith O, Farouk N, Nampoori N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2015;5:49-56.
3. Orasanu G, Plutzky J. The pathologic continuum of diabetic vascular disease. J Am Coll Cardiol. 2009;53(suppl 5):S35-S42.
4. Daehn IS. Glomerular endothelial cell stress and cross-talk with podocytes in early diabetic kidney disease. Front Med (Lausanne). 2018;5:76.
5. Sena CM, Pereira AM, Seiça R. Endothelial dysfunction — a major mediator of diabetic vascular disease. Biochim Biophys Acta. 2013;1832:2216-2231.
6. Störensoss J, Fierlbeck W, Heider T, et al. Glomerular endothelial fenestrae in vivo are not formed from caveolae. J Am Soc Nephrol. 2002;13:2639-2647.
7. Jourde-Chiche N, Fahhoufi F, Dou L, et al. Endothelium structure and function in kidney health and disease. Nat Rev Nephrol. 2019;15:87-108.
8. Shimomura H, Spiro RG. Studies on macromolecular components of human glomerular basement membrane and alterations in diabetes: decreased levels of heparan sulfate proteoglycan and laminin. Diabetes. 1987;36:374-381.
9. Greka A, Mundel P. Cell biology and pathology of podocytes. Ann Rev Physiol. 2012;74:299-323.
10. Park J, Shrestha R, Qiu C, et al. Single-cell transcriptomics of the mouse kidney reveals potential cellular targets of kidney disease. Science. 2018;360:758-763.
11. Wu H, Malone AF, Donnelly EL, et al. Single-cell transcriptomics of a human kidney allograft biopsy specimen defines a diverse inflammatory response. J Am Soc Nephrol. 2018;29:2069-2080.
12. Karaiskos N, Rahmatollahi M, Boltengagen A, et al. A single-cell transcriptome atlas of the mouse glomerulus. J Am Soc Nephrol. 2018;29:2060-2068.
13. Medeiros T, Myette RL, Almeida JR, Silva AA, Burger D. Extracellular vesicles: cell-derived biomarkers of glomerular and tubular injury. Cell Physiol Biochem. 2020;54:88-109.
14. Wu X, Gao Y, Xu L, et al. Exosomes from high glucose-treated glomerular endothelial cells trigger the epithelial-mesenchymal transition and dysfunction of podocytes. Sci Rep. 2017;7:9371.
15. Abe H, Sakurai A, Ono H, et al. Urinary exosomal mRNA of WT1 as diagnostic and prognostic biomarker for diabetic nephropathy. J Med Invest. 2018;65:208-215.
16. Eremina V, Sood M, Haigh J, et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest. 2003;111:707-716.
17. Sison K, Eremina V, Baelde H, et al. Glomerular structure and function require paracrine, not autocrine, VEGF–VEGFR-2 signaling. J Am Soc Nephrol. 2010;21:1691-1701.
18. Veron D, Villegas G, Aggarwal PK, et al. Acute podocyte vascular endothelial growth factor (VEGF-A) knockdown disrupts alphaVbeta3 integrin signaling in the glomerulus. PLoS One. 2012;7:e40589.
19. Ghayur A, Margetts PJ. Transforming growth factor-beta and the glomerular filtration barrier. Kidney Res Clin Pract. 2013;32:3-10.
20. Hata A, Chen Y-G. TGF-β signaling from receptors to smads. Cold Spring Harb Perspect Biol. 2016;8:a022061.
21. ten Dijke P, Arthur HM. Extracellular control of TGFβ signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007;8:857-869.
22. Yamamoto T, Noble NA, Cohen AH, et al. Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int. 1998;49:461-469.
23. Ito Y, Goldschmeding R, Kasuga H, et al. Expression patterns of connective tissue growth factor and of TGF-β isoforms during glomerular injury recapitulate glomerulogenesis. Am J Physiol Renal Physiol. 2010;299:F545-F558.
24. Blank U, Seto ML, Adams DC, Wojchowski DM, Karolak MJ, Oxburgh L. An in vivo reporter of BMP signaling in organogenesis reveals targets in the developing kidney. BMC Dev Biol. 2008;8:86.
25. Schiffer M, Bitzer M, Roberts ISD, et al. Apoptosis in podocytes induced by TGF-β and Smad7. *J Clin Invest.* 2001;108:807-816.

26. Xu J, Lamouille S, Deryck R. TGF-β-induced epithelial to mesenchymal transition. *Cell Res.* 2009;19:156-172.

27. Ying Q, Wu G. Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update. *Ren Fail.* 2017;39:474-483.

28. Xavier S, Vasko R, Matsumoto K, et al. Curtailing endothelial TGF-β signaling is sufficient to reduce endothelial-mesenchymal transition and fibrosis in CKD. *J Am Soc Nephrol.* 2015;26:817-829.

29. Jeansson M, Gavlík A, Anderson G, et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. *J Clin Invest.* 2011;121:2278-2289.

30. Davis B, Dei Cas A, Long DA, et al. Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. *J Am Soc Nephrol.* 2007;18:2320-2329.

31. Sun H, Zheng J, Chen S, Liu Z, Li L. Enhanced expression of ANGPTL2 in the microvascular lesions of diabetic glomeropathy. *Neprhon Exp Nephrol.* 2007;105:e117-e123.

32. Takabatake Y, Sugiyama T, Kohara H, et al. The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature. *J Am Soc Nephrol.* 2009;20:1714-1723.

33. Sayeed SG, Hägele H, Kulkarni OP, et al. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. *Diabetologia.* 2009;52:2445-2454.

34. Reidy KJ, Villegas G, Teichman J, et al. Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development. *Development.* 2009;136:3979-3989.

35. Villegas G, Tufo A. Ontogeny of semaphorins 3A and 3F and their receptors neuropilins 1 and 2 in the kidney. *Mech Dev.* 2002;119(suppl 1):S149-S153.

36. Leung WK, Gao L, Siu PM, Lai CW. Diabetic nephropathy and endothelial dysfunction: current and future therapies, and emerging of vascular imaging for preclinical renal-kinetic study. *Life Sci.* 2016;166:121-130.

37. Brasacchio D, Okabe J, Tikellis C, et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. *Diabetes.* 2009;58:1229-1236.

38. Stenhouver CDA, Andreas Fischer HR, Van Kuijk AWR, Polak BCP, Donker AJM. Endothelial dysfunction precedes development of microalbuminuria in IDDM. *Diabetes.* 1995;44:561-564.

39. Clausen P, Feldt-Rasmussen B, Jensen G, Jensen J. Endothelial haemostatic factors are associated with progression of urinary albumin excretion in clinically healthy subjects: a 4-year prospective study. *Clin Science (London, England).* 1999;97:37-43.

40. Kaiser N, Sasson S, Feener EP, et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. *Diabetes.* 1993;42:80-89.

41. De Bock K, Georgiadou M, Schoors S, et al. Role of PFKFB3-driven glycolysis in vessel sprouting. *Cell.* 2013;154:651-663.

42. Imasawa T, Obre E, Bellance N, et al. High glucose reparatons human podocyte energy metabolism during differentiation and diabetic nephropathy. *FASEB J.* 2017;31:294-307.

43. Wang W, Wang Y, Long J, et al. Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells. *Cell Metab.* 2012;15:186-200.

44. Daehn I, Casalena G, Zhang T, et al. Endothelial mitochondrial oxidative stress determines podocyte depletion in segmental glomerulosclerosis. *J Clin Invest.* 2014;124:1608-1621.

45. Lemkes BA, Nieuwdorp M, Hoekstra JBL, Holleman F. The glycoalky and cardiovascular disease in diabetes: should we judge the endothelium by its cover? *Diabetes Technol Ther.* 2012;14(suppl 1):S-3.

46. Nieuwdorp M, Mooij HL, Kroon J, et al. Endothelial glycoalkry damage coincides with microalbuminuria in type 1 diabetes. *Diabetes.* 2006;55:1127-1132.

47. Nieuwdorp M, Holleman F, de Groot E, et al. Perturbation of hyaluronal metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis. *Diabetologia.* 2007;50:1288-1293.

48. Shakya S, Wang Y, Mack JA, Maytin EV. Hyperglycemia-induced changes in hyaluronal contribute to impaired skin wound healing in diabetes: review and perspective. *Int J Cell Biol.* 2015;2015:701738.

49. Yilmaz O, Afsar B, Ortiz A, Kanbay M. The role of endothelial glycocalyx in health and disease. *Clin Kidney J.* 2019;12:611-619.

50. Kennett EC, Davies MJ. Degradation of matrix glycosaminoglycans by peroxynitrite/peroxynitrous acid: Evidence for a hydroxy-radical-like mechanism. *Free Radic Biol Med.* 2007;42:1278-1289.

51. Kennett EC, Davies MJ. Glycosaminoglycans are fragmented by hydroxyl, carbonate, and nitrogen dioxide radicals in a site-selective manner: implications for peroxynitrite-mediated damage at sites of inflammation. *Free Radic Biol Med.* 2009;47:389-400.

52. Chow FY, Nikolaic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch G. Monocyte chemotactant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. *Kidney Int.* 2006;69:73-80.

53. Navarro-González JF, Mora-Fernández C, de Fuentes MM, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. *Nat Rev Nephrol.* 2011;7:327-340.

54. Hirata K, Shikata K, Matsuda M, et al. Increased expression of selectins in kidneys of patients with diabetic nephropathy. *Diabetesologia.* 1998;41:185-192.

55. Clausen P, Jacobsen P, Rossing K, Jensen JS, Parving HH, Feldt-Rasmussen B. Plasma concentrations of VCAM-1 and ICAM-1 are elevated in patients with type 1 diabetes mellitus with microalbuminuria and overt nephropathy. *Diabet Med.* 2000;17:644-649.

56. Alghamdi T, Batchu SN, Hadden MJ, et al. Histone H3 serine 10 phosphorylation facilitates endothelial activation in diabetic kidney disease. *Diabetes.* 2018;67:2668-2681.

57. Fan L, He X, Muraoy A, Fan F, Roman RJ. Increased renal expression of adhesion molecules and inflammation in diabetic nephropathy. *FASEB J.* 2019;33:573-577.

58. Fu J, Akat KM, Sun Z, et al. Single-cell RNA profiling of glomerular cells shows dynamic changes in experimental diabetic kidney disease. *J Am Soc Nephrol.* 2019;30:533-545.

59. Wilson PC, Wu H, Kinta Y, et al. The single-cell transcriptomic landscape of early human diabetic nephropathy. *Proc Natl Acad Sci U S A.* 2019;116:19819-19825.

60. Siddiqi FS, Advani A. Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes. *Diabetes.* 2013;62:3647-3655.

61. Doublier S, Salvidio G, Lupia E, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycanated albumin and angiotensin II. *Diabetes.* 2003;52:1023-1030.
62. Welsh GI, Saleem MA. Nephrin—signature molecule of the glomerular podocyte? J Pathol. 2010;220:328-337.
63. Sonneveld R, van der Vlag J, Baltissen MPA, et al. Glucose specifically regulates TRPC6 expression in the podocyte in an AngII-dependent manner. Am J Pathol. 2014;184:1715-1726.
64. Kanda S, Harita Y, Shibagaki Y, et al. Tyrosine phosphorylation–dependent activation of TRPC6 regulated by PLC-γ1 and nephrin: effect of mutations associated with focal segmental glomerulosclerosis. Mol Biol Cell. 2011;22:1824-1835.
65. Harita Y, Kurihara H, Kosako H, et al. Phosphorylation of nephrin triggers Ca2+ signaling by recruitment and activation of phospholipase C-γ1. J Biol Chem. 2009;284:8951-8962.
66. Reiser J, Polu KR, M€iller CC, et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet. 2005;37:794-799.
67. Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 gene causes familial focal segmental glomerulosclerosis. Science. 2005;308:1801-1804.
68. Eckel J, Lavin PJ, Finch EA, et al. TRPC6 enhances angiotensin II-induced albuminuria. J Am Soc Nephrol. 2011;22:526-535.
69. Lu XY, Liu BC, Cao YZ, et al. High glucose reduces expression of podocin in cultured human podocytes by stimulating TRPC6. Am J Physiol Renal Physiol. 2019;317:F1605-F1611.
70. Na J, Sweetwyne MT, Park ASD, Susztak K, Cagan RL. Diet-induced podocyte dysfunction in drosophila and mammals. Cell Rep. 2015;12:636-647.
71. Su J, Li SJ, Chen ZH, et al. Evaluation of podocyte lesion in patients with diabetic nephropathy: Wilms’ tumor-1 protein used as a podocyte marker. Diabetes Res Clin Pract. 2010;87:167-175.
72. Tufro A, Veron D. VEGF and podocytes in diabetic nephropathy. Semin Nephrol. 2012;32:385-393.
73. Fukuda A, Chowdhury MA, Venkatareddy MP, et al. Growth-dependent podocyte failure causes glomerulosclerosis. J Am Soc Nephrol. 2012;23:1351-1363.
74. Nagata M, Schärer K, Kriz W. Glomerular damage after uninephrectomy in young rats. I. Hypertrophy and distortion of capillary architecture. Kidney Int. 1992;42:136-147.
75. Young BA, Johnson RJ, Alpers CE, et al. Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int. 1995;47:935-944.
76. Kreidberg JA, Donovan MJ, Goldstein SL, et al. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development. 1996;122:3537-3547.
77. Susztak K, Raff AC, Schiffer M, Bottinger EP. Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2005;55:225-233.
78. Jim B, Ghanta M, Qipo A, et al. Dysregulated nephrin in diabetic nephropathy of type 2 diabetes: a cross sectional study. PLoS One. 2012;7:e36041.
79. Coward RJM, Welsh GI, Koziell A, et al. Nephrin is critical for the action of insulin on human glomerular podocytes. Diabetes. 2007;56:1127-1135.
80. Li JJ, Kwak SJ, Jung DS, et al. Podocyte biology in diabetic nephropathy. Kidney Int Suppl. 2007;72:S36-S42.
81. Ziyadeh FN. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis. 1993;22:736-744.
82. Kriz W, Lemley KV. A potential role for mechanical forces in the detachment of podocytes and the progression of CKD. J Am Soc Nephrol. 2015;26:258-269.
83. Shirato I, Sakai T, Kimura K, Tomino Y, Kriz W. Cytoskeletal changes in podocytes associated with foot process effacement in Masugi nephritis. Am J Pathol. 1996;148:1283-1296.
84. Kriz W, Shirato I, Nagata M, LeHir M, Lemley KV. The podocyte’s response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol. 2012;304:F333-F347.
85. Jerums G, Premararthe E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010;53:2093-2104.
86. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia. 2009;52:691-697.
87. Chen HC, Chen CA, Guh JY, Chang JM, Shin SJ, Lai YH. Altering expression of α3β1 integrin on podocytes of human and rats with diabetes. Life Sci. 2000;67:2345-2353.
88. Han SH, Yang S, Jung DS, et al. Gene expression patterns in glucose-stimulated podocytes. Biochem Biophys Res Commun. 2008;370:514-518.
89. Østerby R, Nyberg G. New vessel formation in the renal corpuscles in advanced diabetic glomerulopathy. J Diabetic Complications. 1987;1:127-122.
90. Oltean S, Qiu Y, Ferguson JK, et al. Vascular endothelial growth factor-a165b is protective and restores endothelial glycocalyx in diabetic nephropathy. J Am Soc Nephrol. 2015;26:1889-1904.
91. Feliers D, Chen X, Aks N, Choudhury GG, Madaio M, Kasinath BS. VEGF regulation of endothelial nitric oxide synthase in glomerular endothelial cells. Kidney Int. 2005;68:1648-1659.
92. Lenoir O, Milon M, Vrsolov A, et al. Direct action of endothelin-1 on podocytes promotes diabetic glomerulosclerosis. J Am Soc Nephrol. 2014;25:1050-1062.
93. Flyvbjerg A, Dagnæs-Hansen F, De Vriese AS, Schrijvers BF, Fogarty DG. Is hyperfiltration a signature molecule of the diabetic nephropathy signature? Diabetes. 2005;54:2891-2903.
94. Zhang SX, Wang JJ, Lu K, Mott R, Longeras R, Ma J. Thera- peutic potential of angiostatin in diabetic nephropathy. J Am Soc Nephrol. 2006;17:475-486.
95. Ichinose K, Maeshima Y, Yamamoto Y, et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes. 2005;54:2891-2903.
96. Dhaun N, MacIntyre IM, Kerr D, et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension. 2011;57:772-779.
97. Kaiser D, Andress DL, Parving HH, et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet. 2019;393:1937-1947.
98. Moon J-A, Kim H-T, Cho I-S, Sheen YY, Kim D-K, IN-. IN-1130, €€. 2004;26:1835.
99. Schrijvers BF, Fogarty DG. Is hyperfiltration a signature molecule of the diabetic nephropathy signature? Diabetes. 2005;54:2891-2903.
100. Gil et al
101. Petersen M, Thorikay M, Deckers M, et al. Oral administration of GW788388, an inhibitor of TGF-β type I and II receptor kinases, decreases renal fibrosis. Kidney Int. 2008;73:705-715.
102. Hovind P, Tarnow L, Oestergaard PB, Parving H-H. Elevated vascular endothelial growth factor in type 1 diabetic patients with diabetic nephropathy. Kidney Int Suppl. 2000;57:S56-S61.

103. Iglesias-de la Cruz MC, Ziyadeh FN, Isono M, et al. Effects of high glucose and TGF-β1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int. 2002;62:901-913.

104. Hoshi S, Nomoto K, Kuromitsu J, Tomari S, Nagata M. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem Biophys Res Commun. 2002;290:177-184.

105. McCarty G, Awad O, Loeb DM. WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia. J Biol Chem. 2011;286:43634-43643.

106. Tsuchida K, Makita Z, Yamagishi S, et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia. 1999;42:579-588.

107. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol. 2003;162:1123-1137.

108. van der Vlag J, Buijsers B. The glomerular endothelium in diabetic nephropathy: role of heparanase. In: Roelofs JJ, Vogt L, eds. Diabetic Nephropathy: Pathophysiology and Clinical Aspects. Springer Int Publishing; 2019:153-170.

109. Guo M, Ricardo SD, Deane JA, Shi M, Cullen-McEwen L, Bertram JF. A stereological study of the renal glomerular vasculature in the db/db mouse model of diabetic nephropathy. J Anat. 2005;207:813-821.

110. Liu E, Morimoto M, Kitajima S, et al. Increased expression of vascular endothelial growth factor in kidney leads to progressive impairment of glomerular functions. J Am Soc Nephrol. 2007;18:2094-2104.

111. Majumder S, Advani A. VEGF and the diabetic kidney: more than too much of a good thing. J Diabetes Complications. 2017;31:273-279.

112. Zheng GH, Shan Q, Mu JJ, et al. Purple sweet potato color attenuates kidney damage by blocking VEGFR2/ROS/NLRP3 signaling in high-fat diet-treated mice. Oxid Med Cell Longev. 2019;2019:5189819.

113. Ratliff BB, Abdulmahdi W, Pawar R, Wolin MS. Oxidant mechanisms in renal injury and disease. Antioxid Redox Signal. 2016;25:119-146.

114. Falkevall A, Mehlem A, Palombo I, et al. Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease. Cell Metab. 2017;25:713-726.

115. Onions KL, Gamez M, Buckner NR, et al. VEGFC reduces glomerular albumin permeability and protects against alterations in VEGF receptor expression in diabetic nephropathy. Diabetes. 2019;68:172-187.

116. Pozzi A, Zent R. Integrins in kidney disease. J Am Soc Nephrol. 2013;24:1034.

117. Ak G, Buyukberber S, Sevinc A, et al. The relation between plasma endothelin-1 levels and metabolic control, risk factors, treatment modalities, and diabetic microangiopathy in patients with Type 2 diabetes mellitus. J Diabetes Complications. 2001;15:150-157.

118. Monig M, Buelli S, Zanchi C, et al. Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. Am J Pathol. 2006;169:1965-1975.

119. Ebeffors K, Wiener RJ, Yu L, et al. Endothelin receptor-A mediates degradation of the glomerular endothelial surface layer via pathologic crosstalk between activated podocytes and glomerular endothelial cells. Kidney Int. 2019;96:957-970.

120. Baelde HJ, Eikmans M, Lappin DWP, et al. Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss. Kidney Int. 2007;71:637-645.

121. Vriese ASD, Tilton RG, Elger M, Stephan CC, Kriz W, Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol. 2001;12:993-1000.

122. Tian H, Yang J, Xie Z, Liu J. Gliquidone alleviates diabetic nephropathy by inhibiting notch/snail signaling pathway. Cell Physiol Biochem. 2018;51:2085-2097.

123. Lee S, Kim W, Moon SO, et al. Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes. Nephrol Dial Transplant. 2006;22:396-408.